look competit
bmy/exel announc top-lin result rcc
nivolumab cabozantinib beat sunitinib primari endpoint
hr median follow-up month data present
upcom meet dataset key return growth rcc
view dataset strongest limit dataset within rcc combin exhibit
see insid previous rcc growth stunt introduct keytruda
inlyta seem competit increas market model
model greater cabo use vs prior us rcc sale increas
pt result bode well addit combo
rcc nivolumab cabozantinib beat sunitinib primari
os also show improv hr median follow-up
axitinib os follow-up
avelumab axitinib javelin renal follow-up
nivolumab ipilimumab use lost market share pembrolizumab axitinib
post launch believ fulli comit market nivolumab
cabozantinib rcc recuper rcc market share via nivolumab
sale addit nivolumab cabozantinib seem efficaci overal
popul vs nivolumab ipilimumab need see additon data on-going
cabo nivo ipi anoth commit option
view strong data posit read-across trial
cabozantinib atezolizumab test across mani histolog
basket trial date mcrpc nsclc cohort expand
could pivot expect nsclc data year
cabo atezolizumab report pivot interim data
base top-line data updat rcc forecast vs prior
total us rcc sale rcc royalti ex-u sale increas
cabozantinib nivolumab market share prior conserv
assum inferior data vs pembrolizumab axitinib increas pt
updat script ahead notic increas nrx vs
cabozantinib sale forecast mainli driven
larger data drive growth rcc post approv
view potenti faster month post file sinc agent approv
keytruda inlyta
year price histori exelixi
compani discov develop
small molecul therapeut
treatment cancer
analyst certif import disclosur see disclosur
estim cabometyx sale includ addit indic
increas plu un-risk-adjust addit
estim cometriq sale increas
collabor royalti revenu expect increas
view well posit deliv near-term top-lin
growth expans cabozantinib best-in-class
tki addit tumor type pipelin could
deliv valu sever near-term catalyst
cabo/nivo checkmat data preset rcc
data basket trial
atezolizumab tecentriq solid tumor
data
estim sell price four experiment product
low price increas exist product would
upsid earn estim
cabometyx cometriq fail gain addit market penetr
cabometyx fail receiv fda approv addit
indic revenu could reduc
valu base dcf valuat discount rate termin valu growth rate estim peak cabometyx
sale us pipelin model risk-adjust peak cabometyx sale probabl
success risk-adjust peak dtc sale uc po
believ growth next five year depend heavili continu success cabometyx cometriq genentech
success partner product cotel unforese reason includ competit patient behavior physician adopt loss
patent protect structur chang healthcar market penetr product could stall therebi diminish contribut
sale ep
exhibit opdivo cabozantinib interim analysi month median follow-up
trial met primari endpoint importantli secondari
endpoint os also show improv hr orr also beat compar
arm valu provid safeti data line nivolumab cabozantinib monotherapi
regimen trial low frequenc treatment discontinu data present
upcom meet
exhibit quick take opdivo cabozantinib vs keytruda inlyta detail
data key subgroup total os valu present upcom
meet overal current hr number point compar data better
treatment pembro mg everi three week axitinib mg twice daili sunitinib
mg daili four week follow two week patient pembro arm may
receiv dose pembro axitinib-onli treatment may continu
enrol popul pt random pembro axi sunitinib
exhibit bl demograph enrol patient
exhibit result patient publish nejm month follow-up os
benefit observ subgroup examin includ imdc risk express
categori howev trend toward efficaci higher imdc risk group higher
os median os reach either group risk death lower
pembrolizumabaxitinib group vs sunitinib group hr ci
 median month ci pembrolizumabaxitinib group
month ci sunitinib group hr ci
exhibit updat data month follow-up popul present
os median os reach either group risk death lower
pembrolizumabaxitinib group vs sunitinib group hr ci
 median month ci pembrolizumabaxitinib
group month ci sunitinib group hr ci
treatment avelumab administ mg/kg iv everi two week combin
axitinib mg po bid sunitinib given mg po qd schedul
enrol popul patient assign receiv avelumab plu axitinib
patient sunitinib patient total patient receiv trial treatment
receiv avelumab plu axitinib receiv sunitinib patient
tumor patient tumor-tissu sampl
avail assess
exhibit bl demograph enrol patient
exhibit result patient javelin renal avelumab axitinib vs sunitinib
benefit observ posit comer popul os data avail
popul median popul month
confid interv ci could estim avelumab plu axitinib
compar month ci sunitinib hr
patient median month ci could estim
avelumab plu axitinib compar month ci sunitinib hr
week four dose follow nivolumab monotherapi mg/kg iv everi two week
ii sunitinib mg oral daili four week follow two week
enrol popul elig patient randomli assign nivolumab plu
ipilimumab sunitinib vs intention-to-treat popul vs
intermediate-risk poor-risk patient vs favourable-risk patient
exhibit bl demograph enrol patient
exhibit intention-to-treat popul includ risk group
os median os reach nivolumab ipilimumab versu month
sunitinib hr ci
 median month ci nivolumab plu ipilimumab versu
month sunitinib hr ci separ curv
occur post month plateau reach month
exhibit intermediate-risk poor-risk patient primari efficaci popul trial
os median os reach ci nivolumab plu ipilimumab versu
month sunitinib hr ci
 median month ci nivolumab plu ipilimumab versu
month sunitinib hr ci separ curv
occur post month plateau reach month
os os similar two group overal surviv
nivolumab plu ipilimumab versu sunitinib
differ significantli treatment group progression-fre
surviv nivolumab plu ipilimumab versu sunitinib
drug/indicationexpect launchpeak sale estim mm unadjust npv valueest probabl successp-adj npv mm p-adj valu sharecabometyx cometriq ici tki equiti share outstand use valuat oppenheim co
exhibit dcf model base top-line data updat rcc forecast vs
prior total us rcc sale rcc royalti ex-u sale increas
cabozantinib nivolumab market share prior conserv assum inferior data
vs pembrolizumab axitinib increas pt prior
discount except per-shar data thousand except per-shar data revenu growth chang work chang work capit valu growth valu oppenheim valu per sharetermin valu growth rateequ valu per shareprob success cabozantinib probabl cabozantinib dtc outperform
probabl success
probabl success
collabor revenu mileston
good
royalti revenu
research devleop
adjust research develop non-gaap
share-bas compens
total share-bas compenst
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compenst
total share-bas compens exclud non-gaap
total non-oper income/ expens
earn tax loss
bristol-my squibb co bmy-nys cover
merck co inc mrk-nyse cover
pfizer inc pfe-nys cover
